<DOC>
	<DOCNO>NCT00990405</DOCNO>
	<brief_summary>The role Helicobacter pylorus infection functional dyspepsia remain controversial . Several randomize controlled trial western country show significant advantage placebo . But recent study Asian population different compare result study Western population . At present time , seem difficult conclude efficacy H.pylori eradication therapy patient H. pylori-infected functional dyspepsia . The investigator hypothesize eradication Helicobacter pylorus sustain global symptom improvement patient H. pylori infect functional dyspepsia .</brief_summary>
	<brief_title>Clinical Study Evaluate Efficacy Safety Eradication Therapy Helicobacter Pylori Functional Dyspepsia</brief_title>
	<detailed_description>Functional dyspepsia : diagnose Rome III criterion Functional gastrointestinal disorder Treatment regimen : Combination proton pump inhibitor , Amoxicillin , Clarithromycin 7 day Placebo : Same shape placebo drug</detailed_description>
	<mesh_term>Dyspepsia</mesh_term>
	<mesh_term>Helicobacter Infections</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<criteria>Functional dyspepsia Rome III criterion Normal endoscopic finding H. pylori positive Urea breath test Patients severe concomitant systemic disease Patients GI surgery Females pregnancy breastfeed Irritable bowel syndrome , inflammatory bowel disease Duodenal Ulcer , Gastric Ulcer , GI bleed History eradication therapy Helicobacter pylorus Malignancy Psychosomatic disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Rome III criterion</keyword>
</DOC>